NVAX Novavax Net earnings per share growth forecast for next year

Is it worth investing in Novavax, Inc. (NVAX), given the acceleration of vaccine development through AI protein modeling? The GURU.Markets terminal displays a chart of the forward net income growth rate, where the current reading is -761.80. The business model is based on US R&D centers with outsourced manufacturing. Meanwhile, John Jacobs' management has successfully stabilized the company through licensing agreements, restoring market confidence.

Novavax Corp (NVAX): Projected earnings per share growth rate for next year from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Novavax (NVAX)

- stock quotes and analyst forecast:

Stock Quotes Novavax Pharma|NVAX - Analyst Consensus Forecast

- market capitalization data:

Market Value Novavax Pharma|NVAX - Company Buyout Price

- company book value details:

Net Assets per Single Share Novavax|NVAX - Accounting Capitalization|Market Value to Book Value Ratio novavax.com|NVAX - Company Assets

- debt and liquidity data:

- net income and valuation ratios data:

NVAX - Company Profit|Future Profit Novavax, Inc.|NVAX - Company Value to Net Income|Forward P/E Multiple Novavax Inc|NVAX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Novavax Pharma|NVAX - Operating profit before amortization|Net earnings per share (EPS TTM) Novavax|NVAX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months novavax.com|NVAX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Novavax, Inc.

- issuer revenue and sales details:

NVAX - Company Sales Volume|Company Future Sales Volume Novavax, Inc.|NVAX - Price-to-Revenue Ratio|Forward P/S Multiple Novavax, Inc.|NVAX - Sales Growth YoY (TTM)

Basic company analysis:Novavax, Inc.

This indicator measures the expected percentage difference between current and future net earnings per share, reflecting the market's implied rate of business expansion. The trend in consensus EPS forecasts for the coming year for Novavax, Inc. (NVAX) demonstrates the company's ability to monetize the transition to combination vaccines and new partnerships, determining the long-term sustainability of share prices amid the saturation of the monovalent vaccine market.

Key competitors